文献速递放疗物理与技术头颈部肿瘤放疗消化道肿瘤放疗

澳大利亚碳离子放射治疗(CIRT)适应症及符合条件患者数量的国际估算方法

An international approach to estimating the indications and number of eligible patients for carbon ion radiation therapy (CIRT) in Australia.
PubMed 文献 · Radiother Oncol · 2023-07-20

专家小组包括四家运营中和两家拟建国际碳离子设施的代表的及新南威尔士州利益相关方,通过虚拟会议及会前会后资料评估CIRT证据。结果显示澳大利亚目前可合理用于头颈部腺样囊性癌和黏膜黑色素瘤、肝细胞癌和肝转移、颅底脑膜瘤、脊索瘤和软骨肉瘤,每年近1400例患者符合共识适应症。保守估计1%癌症患者或2%放疗推荐患者可能优先受益,支持建设一家最多四个治疗室的国家碳离子设施。

要点

  • 澳大利亚目前可合理开展CIRT的共识适应症包括头颈部腺样囊性癌和黏膜黑色素瘤、肝细胞癌和肝转移、颅底脑膜瘤、脊索瘤和软骨肉瘤。
  • 每年近1400例澳大利亚患者符合共识衍生的适应症。
  • 保守估计1%澳大利亚癌症患者或2%放疗推荐患者可能优先受益于CIRT。

核心结论

  • 保守估计1%的澳大利亚癌症患者(或2%的放疗推荐患者)可能优先受益于CIRT,用于放射抵抗肿瘤的初始治疗、其他治疗后持续活动疾病的推量或复发疾病的再程放疗。
  • 基于此,一家最多四个治疗室的国立碳离子设施对澳大利亚患者是合理的。

研究设计与样本

  • 召集专家小组,包括四家运营中和两家拟建国际碳离子设施的代表以及新南威尔士州CIRT利益相关方,举行虚拟会议审议CIRT现有证据和经验。
  • 会前和会后提供日本CIRT信息,讨论中纳入韩国已发表信息。

主要发现

  • CIRT治疗的肿瘤存在辖区差异,原因包括某些肿瘤发病率不同、转诊模式、优先治疗肿瘤决策差异、可用CIRT资源和资助安排不同。
  • 共识程度最高的是澳大利亚目前可合理将CIRT用于头颈部腺样囊性癌和黏膜黑色素瘤、肝细胞癌和肝转移、颅底脑膜瘤、脊索瘤和软骨肉瘤患者。
  • 目前每年近1400例澳大利亚患者符合共识衍生的适应症。

关键数值与推荐

  • 澳大利亚目前可合理开展CIRT的共识适应症:头颈部腺样囊性癌和黏膜黑色素瘤、肝细胞癌和肝转移、颅底脑膜瘤、脊索瘤和软骨肉瘤。
  • 每年近1400例澳大利亚患者符合共识衍生的适应症。
  • 保守估计1%的澳大利亚癌症患者(或2%的放疗推荐患者)可能优先受益于CIRT。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To establish the treatment indications and potential patient numbers for carbon ion radiation therapy (CIRT) at the proposed national carbon ion (and proton) therapy facility in the Westmead precinct, New South Wales (NSW), Australia. METHODS: An expert panel was convened, including representatives of four operational and two proposed international carbon ion facilities, as well as NSW-based CIRT stakeholders. They met virtually to consider CIRT available evidence and experience. Information regarding Japanese CIRT was provided pre- and post- the virtual meeting. Published information for South Korea was included in discussions. RESULTS: There was jurisdictional variation in the tumours treated by CIRT due to differing incidences of some tumours, referral patterns, differences in decisions regarding which tumours to prioritise, CIRT resources available and funding arrangements. The greatest level of consensus was reached that CIRT in Australia can be justified currently for patients with adenoid cystic carcinomas and mucosal melanomas of the head and neck, hepatocellular cancer and liver metastases, base of skull meningiomas, chordomas and chondrosarcomas. Almost 1400 Australian patients annually meet the consensus-derived indications now. CONCLUSION: A conservative estimate is that 1% of cancer patients in Australia (or 2% of patients recommended for radiation therapy) may preferentially benefit from CIRT for initial therapy of radiation resistant tumours, or to boost persistently active disease after other therapies, or for re-irradiation of recurrent disease. On this basis, one national carbon ion facility with up to four treatment rooms is justified for Australian patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Ahern V, Adeberg S, Fossati P, et al. An international approach to estimating the indications and number of eligible patients for carbon ion radiation therapy (CIRT) in Australia. Radiother Oncol. 2023. PMID: 37480996. doi:10.1016/j.radonc.2023.109816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。